All In Biotech

Free tool

FAERS Monitor: Tezspire

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761224 or its brand name (Tezspire, Tezepelumab-Ekko). Reports on generic versions are filed under their own applications.

Reports

6,931

Serious

3,128

45% of reports

Hospitalization

1,280

Death reported

255

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • asthma1,067
  • dyspnoea649
  • drug ineffective552
  • arthralgia551
  • product dose omission issue355
  • cough342
  • pneumonia294
  • fatigue273
  • headache259
  • back pain242
  • rash239
  • pain233
  • injection site pain217
  • dizziness204
  • device leakage199

Reports by year received

View as table
YearReports
20181
20194
20208
20217
2022588
20231,252
20241,589
20251,785
20261,697

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,228 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
asthmaSignal1,06728.927.428,609
device leakageSignal19914.012.22,381
arthralgiaSignal5514.03.71,273
coughSignal3423.73.3681
product dose omission issueSignal3553.73.3695
dyspnoeaSignal6493.53.21,176
back painSignal2423.22.8359
pneumoniaSignal2942.82.5332
injection site painSignal2172.11.9134
rash2391.71.564
drug ineffective5521.31.234
headache2591.31.113
dizziness2041.21.110
pain2331.21.05
fatigue2731.10.91

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.